To fill this gap, we examined PARP1 mRNA expression in a series of 1464 clinical samples of STS, including 1432 primary tumors and 32 relapses, and searched for correlations with clinicopathological features, including metastasis‐free survival (MFS). The gene discussed is PARP1; the disease is telomere syndrome.